期刊文献+

β-肌动蛋白启动子指导下人bcl-2转基因小鼠模型的建立 被引量:4

Establishment of transgenic mouse model carrying bcl-2 under the direction of β-actin promoter
下载PDF
导出
摘要 目的 :通过原核注射法将肌动蛋白启动子 /bcl 2基因转入小鼠受精卵 ,制作转bcl 2基因的小鼠 .方法 :构建 β actin启动子 /bcl 2表达载体 ,小鼠进行超排获得原核期胚胎 ,应用原核注射法进行转基因操作 ,对新生小鼠通过基因组DNAPCR和Southernblot方法进行鉴定 .结果 :注射成功率为5 8% (5 80 / 10 0 0 ) ,新生小鼠为 33只 ,PCR检测转基因阳性为 8只 ,经过Southern杂交检测有 4只转基因阳性鼠 .结论 :通过原核注射法获得转bcl 2基因的阳性小鼠 ,建立bcl 2转基因动物模型 ,为脑缺血再灌注损伤的机制研究提供手段 . AIM: To construct a transgenic mouse model carrying bcl-2 gene by prokaryotic injection of promoter-β-actin-bcl-2. METHODS: The promoter-β-actin-bcl-2 expression vector was constructed and the vector was injected into mouse prokaryotic embryo and the DNA of transgenic mice was identified with PCR and Southern blot. RESULTS: The achievement rate of prokaryotic injection was 58%. Among the 33 newborn mice, 8 were tested to be bcl-2 positive with PCR while Southern blotting identified only 4 bcl-2 positive mice. CONCLUSION: The transgenic mouse model carrying bcl-2 gene has been established by prokaryotic injection, which provides an effective model in studying the mechanism of cerebral ischemia-reperfusion injury.
出处 《第四军医大学学报》 CAS 北大核心 2004年第18期1656-1658,共3页 Journal of the Fourth Military Medical University
基金 国家自然科学基金资助项目 (30 0 70 731 )
关键词 基因 BCL-2 β-肌动蛋白启动子 小鼠 转基因 genes, bcl-2 β-actin promoter mice, transgenic
  • 相关文献

参考文献12

二级参考文献34

  • 1[1]Harold R, Roberts. Molecular biology of hemophilia B. Thromb Haemost, 1993, 70(1):1~9.
  • 2[2]Lin H F, Maeda N, Smithies O et al. A coagulation factor IX-dificient mouse model for human hemophilia B. Blood, 1997, 90(10):3962~3966.
  • 3[3]Wang L, Zoppe M, Hackeng T M et al. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc. Natl. Aced. Sci. USA, 1997, 94(21):11563~11566.
  • 4[4]Ramendra Krishna Kundu, Frank Sangiorgi, Lang-Ying Wu et al. Targeted inactivation of the coagulation factor IX gene cause Hemophilia B in mice. Blood, 1998, 92(1):168~174.
  • 5[5]Giannelli F, Green P M, Sommer S S et al. Haemophilila B: database of point mutations and short additions and deletions-eight edition. Nucleic Acids Res., 1998, 26(1):265~268.
  • 6[6]Hogan B, Beddington R, Costantini F et al. Manipulating the mouse embryo, a laboratory manual. 2nd Ed. Cold spring harbor laboratory press, 1994.
  • 7[7]Ludwig M, Sabharwal A k, Brackmann H H et al. Hemophilia b causeed by five different nondeletion mutations in the protease domain of factor IX. Blood, 1992, 79(5):1225~1232.
  • 8[8]Aloysius Y L, Susan E H, Mark P S. Immune tolerance therapy for haemophilia. Drugs, 2000, 60(3):547~554.
  • 9[9]Randal J, Kaufman. Advances toward gene therapy for hemophilia at the millennium. Human Gene Therapy, 1999, 10:2091~2107.
  • 10[10]Joan Cox Gill. The role of genetics in inhibitor formation. Thrombosis and Haemostasis, 1999, 82(2):500~504.

共引文献143

同被引文献51

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部